Compare Rivian Automotive, Inc. (RIVN) vs Summit Therapeutics Inc (SMMT) Price & Performance

Rivian Automotive (RIVN) trades at $14.33, down slightly by 0.07% on the day, amid a bearish technical outlook but with improving operational trends. The company reported record Q3 2026 deliveries of 19,248 vehicles, beating estimates and reaffirming full-year guidance, though the stock dipped as investors hoped for a forecast upgrade. Financially, revenue growth continues but losses persist, with a net income margin of -54.95% in 2025, while cash burn has moderated from prior years.

The outlook remains challenged by high cash burn and competitive pressures, but cost controls and R2 SUV ramp-up offer a path to profitability. Analyst consensus is cautiously optimistic with a $16.89 price target, though risks include execution delays and EV market volatility. The stock presents a high-risk, high-reward opportunity for investors betting on Rivian's scaling and autonomy initiatives.

Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.

The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.